Sex and exercise interact to alter the expression of anabolic androgenic steroid-induced anxiety-like behaviors in the mouse

Hormones and Behavior

Volumn 66, Issue 2, 2014, Pages 283-297

  Onakomaiya, Marie M ^a   Porter, Donna M ^a   Oberlander, Joseph G ^b   Henderson, Leslie P ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Acoustic startle response; Amygdala; Anabolic androgenic steroids; Anxiety; Bed nucleus of the stria terminalis; Brain derived neurotrophic factor (BDNF); Corticotrophin releasing factor (CRF or CRH); Exercise; Sex specific; Social interaction

Indexed keywords

ANDROGEN; BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOTROPIN RELEASING FACTOR; METANDIENONE; NANDROLONE DECANOATE; TESTOSTERONE CIPIONATE; ANABOLIC AGENT; STEROID;

ABNORMAL BEHAVIOR; ADOLESCENCE; AMYGDALOID NUCLEUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; BEHAVIOR CHANGE; BODY MASS; BRAIN LEVEL; CONTROLLED STUDY; DRUG EFFECT; EXERCISE; EXPERIMENTAL BEHAVIORAL TEST; FEMALE; HIPPOCAMPUS; HUMAN; INTRACELLULAR SIGNALING; LONG TERM EXPOSURE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; TRANQUILIZING ACTIVITY; ANIMAL; ANXIETY; BODY WEIGHT; C57BL MOUSE; CHEMICALLY INDUCED; DECISION MAKING; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PSYCHOLOGY; SEXUAL BEHAVIOR; SEXUAL DEVELOPMENT; SOCIAL BEHAVIOR; STARTLE REFLEX;

ANABOLIC AGENTS; ANDROGENS; ANIMALS; ANXIETY; BODY WEIGHT; CHOICE BEHAVIOR; CORTICOTROPIN-RELEASING HORMONE; FEMALE; MALE; MICE; MICE, INBRED C57BL; PHYSICAL CONDITIONING, ANIMAL; REFLEX, STARTLE; SEX CHARACTERISTICS; SEXUAL BEHAVIOR, ANIMAL; SOCIAL BEHAVIOR; STEROIDS;

EID: 84902281522     PISSN: 0018506X     EISSN: 10956867     Source Type: Journal    
DOI: 10.1016/j.yhbeh.2014.04.008     Document Type: Article

References (145)

1. Abel J.L., Rissman E.F. Running-induced epigenetic and gene expression changes in the adolescent brain. Int. J. Dev. Neurosci. 2013, 31(6):382-390.
2. Adlard P.A., Perreau V.M., Cotman C.W. The exercise-induced expression of BDNF within the hippocampus varies across life-span. Neurobiol. Aging 2005, 26(4):511-520.
3. Agis-Balboa R.C., Pibiri F., Nelson M., Pinna G. Enhanced fear responses in mice treated with anabolic androgenic steroids. Neuroreport 2009, 20(6):617-621.
4. Ågren G., Thiblin I., Tirassa P., Lundeberg T., Stenfors C. Behavioural anxiolytic effects of low-dose anabolic androgenic steroid treatment in rats. Physiol. Behav. 1999, 66:503-509.
5. Alvarez-López M.J., Castro-Freire M., Cosín-Tomás M., Sanchez-Roige S., Lalanza J.F., Del Valle J., Párrizas M., Camins A., Pallás M., Escorihuela R.M., Kaliman P. Long-term exercise modulates hippocampal gene expression in senescent female mice. J. Alzheimers Dis. 2013, 33(4):1177-1190.
6. Ambar G., Chiavegatto S. Anabolic-androgenic steroid treatment induces behavioral disinhibition and downregulation of serotonin receptor messenger RNA in the prefrontal cortex and amygdala of male mice. Genes Brain Behav. 2009, 8:161-173.
7. Annitto W.J., Layman W.A. Anabolic steroids and acute schizophrenic episode. J. Clin. Psychiatry 1980, 41(4):143-144.
8. Aqai P., Cevik E., Gerssen A., Haasnoot W., Nielen W.F. High-throughput bioaffinity mass spectrometry for screening and identification of designer anabolic steroids in dietary supplements. Anal. Chem. 2013, 85:3255-3262.
9. Bahrke M.S., Yesalis C.E., Brower K.J. Anabolic-androgenic steroid abuse and performance-enhancing drugs among adolescents. Child Adolesc. Psychiatr. Clin. N. Am. 1998, 7(4):821-838.
10. Bahrke M.S., Yesalis C.E., Kopstein A.N., Stephens J.A. Risk factors associated with anabolic-androgenic steroid use among adolescents. Sports Med. 2000, 29(6):397-405.
11. Bale T.L., Vale W.W. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu. Rev. Pharmacol. Toxicol. 2004, 44:525-557.
12. Bale T.L., Picetti R., Contarino A., Koob G.F., Vale W.W., Lee K.F. Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior. J. Neurosci. 2002, 22(1):193-199.
13. Bangasser D.A., Valentino R.J. Sex differences in molecular and cellular substrates of stress. Cell. Mol. Neurobiol. 2012, 32(5):709-723.
14. Bangasser D.A., Curtis A., Reyes B.A., Bethea T.T., Parastatidis I., Ischiropoulos H., Van Bockstaele E.J., Valentino R.J. Sex differences in corticotropin-releasing factor receptor signaling and trafficking: potential role in female vulnerability to stress-related psychopathology. Mol. Psychiatry 2010, 15(9):877. (896-904).
15. Bao A.M., Swaab D.F. Sexual differentiation of the human brain: relation to gender identity, sexual orientation and neuropsychiatric disorders. Front. Neuroendocrinol. 2011, 32(2):214-226.
16. Bao A.M., Fischer D.F., Wu Y.H., Hol E.M., Balesar R., Unmehopa U.A., Zhou J.N., Swaab D.F. A direct androgenic involvement in the expression of human corticotropin-releasing hormone. Mol. Psychiatry 2006, 11(6):567-576.
17. Barreto-Estrada J.L., Barreto J., Fortis-Santiago Y., Rivera-Ramos I., Fortis-Santiago A., Jorge J.C. Modulation of affect after chronic exposure to the anabolic steroid 17alpha-methyltestosterone in adult mice. Behav. Neurosci. 2004, 118(5):1071-1079.
18. Benekareddy M., Goodfellow N.M., Lambe E.K., Vaidya V.A. Enhanced function of prefrontal serotonin 5-HT2 receptors in a rat model of psychiatric vulnerability. J. Neurosci. 2010, 30(36):12138-12150.
19. Binder E., Droste S.K., Ohl F., Reul J.M. Regular voluntary exercise reduces anxiety-related behaviour and impulsiveness in mice. Behav. Brain Res. 2004, 155(2):197-206.
20. Bitran D., Kellogg C.K., Hilvers R.J. Treatment with an anabolic-androgenic steroid affects anxiety-related behavior and alters the sensitivity of cortical GABAA receptors in the rat. Horm. Behav. 1993, 27(4):568-583.
21. Blasberg M.E., Clark A.S. Anabolic-androgenic steroid effects on sexual receptivity in ovariectomized rats. Horm. Behav. 1997, 32:201-208.
22. Bronson F.H. Effects of prolonged exposure to anabolic steroid on the behavior of male and female mice. Pharmacol. Biochem. Behav. 1996, 53:329-334.
23. Bronson F.H., Nguyen K.Q., De La Rosa J. Effect of anabolic steroids on behavior and physiological characteristics of female mice. Physiol. Behav. 1996, 59:49-55.
24. Buckman J.F., Farris S.G., Yusko D.A. A national study of substance use behaviors among NCAA male athletes who use banned performance enhancing substances. Drug Alcohol Depend. 2013, 131(1-2):50-55.
25. Burghardt P.R., Fulk L.J., Hand G.A., Wilson M.A. The effects of chronic treadmill and wheel running on behavior in rats. Brain Res. 2004, 1019(1-2):84-96.
26. Burnett K.F., Kleiman M.E. Psychological characteristics of adolescent steroid users. Adolescence 1994, 29(113):81-89.
27. Cameron O.G., Hill E.M. Women and anxiety. Psychiatr. Clin. N. Am. 1989, 12(1):175-186.
28. Canteras N.S., Resstel L.B., Bertoglio L.J., Carobrez Ade P., Guimarães F.S. Neuroanatomy of anxiety. Curr. Top. Behav. Neurosci. 2010, 2:77-96.
29. Carbone D.L., Handa R.J. Sex and stress hormone influences on the expression and activity of brain-derived neurotrophic factor. Neuroscience 2013, 239:295-303.
30. Clark A.S., Henderson L.P. Behavioral and physiological responses to anabolic-androgenic steroids. Neurosci. Biobehav. Rev. 2003, 27(5):413-436.
31. Clark A.S., Harrold E.V., Fast A.S. Anabolic-androgenic steroid effects on the sexual behavior of intact male rats. Horm. Behav. 1997, 31(1):35-46.
32. Clark A.S., Costine B.A., Jones B.L., Kelton-Rehkopf M.C., Meerts S.H., Nutbrown-Greene L.L., Penatti C.A.A., Porter D.M., Yang P., Henderson L.P. Sex- and age-specific effects of anabolic androgenic steroids on reproductive behaviors and on GABAergic transmission in neuroendocrine control regions. Brain Res. 2006, 1126:122-138.
33. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Lawrence Earlbaum Associates, Hillsdale, NJ. 2nd ed.
34. Cooper R.L., Goldman J.M., VandenBergh J.G. Monitoring of the estrous cycle in the laboratory rodent by vaginal lavage. Methods in Toxicology 1993, 45-55. Academic Press, New York, NY. J.J. Heindel, R.E. Chapin (Eds.).
35. Cooper C.J., Noakes T.D., Dunne T., Lambert M.I., Rochford K. A high prevalence of abnormal personality traits in chronic users of anabolic-androgenic steroids. Br. J. Sports Med. 1996, 30(3):246-250.
36. Costine B.A., Oberlander J.G., Davis M.C., Penatti C.A., Porter D.M., Leaton R.N., Henderson L.P. Chronic anabolic androgenic steroid exposure alters corticotropin releasing factor expression and anxiety-like behaviors in the female mouse. Psychoneuroendocrinology 2010, 35(10):1473-1485.
37. Crawley J.N. What's Wrong with my Mouse? Behavioral Phenotying of Transgenic and Knockout Mice 2000, Wiley-Liss, New York, NY USA, (pp 54-55).
38. Crawley J.N. Mouse behavioral assays relevant to the symptoms of autism. Brain Pathol. 2007, 17(4):448-459.
39. Cunningham R.L., Lumia A.R., McGinnis M.Y. Androgenic anabolic steroid exposure during adolescence: ramifications for brain development and behavior. Horm. Behav. 2013, 64(2):350-356.
40. Davis M., Walker D.L., Miles L., Grillon C. Phasic versus sustained fear in rats and humans: role of the extended amygdala in fear versus anxiety. Neuropsychopharmacology 2010, 35:105-135.
41. Deacon R.M. Digging and marble burying in mice: simple methods for in vivo identification of biological impacts. Nat. Protoc. 2006, 1(1):122-124.
42. Desbonnet L., Garrett L., Daly E., McDermott K.W., Dinan T.G. Sexually dimorphic effects of maternal separation stress on corticotrophin-releasing factor and vasopressin systems in the adult rat brain. Int. J. Dev. Neurosci. 2008, 26(3-4):259-268. (2008).
43. Dong H.W., Swanson L.W. Projections from bed nuclei of the stria terminalis, dorsomedial nucleus: implications for cerebral hemisphere integration of neuroendocrine, autonomic, and drinking responses. J. Comp. Neurol. 2006, 494(1):75-107.
44. Dong H.W., Petrovich G.D., Swanson L.W. Topography of projections from amygdala to bed nuclei of the stria terminalis. Brain Res. Brain Res. Rev. 2001, 38(1-2):192-246.
45. Droste S.K., Gesing A., Ulbricht S., Müller M.B., Linthorst A.C., Reul J.M. Effects of long-term voluntary exercise on the mouse hypothalamic-pituitary-adrenocortical axis. Endocrinology 2003, 144(7):3012-3023.
46. Droste S.K., Schweizer M.C., Ulbricht S., Reul J.M. Long-term voluntary exercise and the mouse hypothalamic-pituitary-adrenocortical axis: impact of concurrent treatment with the antidepressant drug tianeptine. J. Neuroendocrinol. 2006, 18(12):915-925.
47. Duman C.H., Schlesinger L., Russell D.S., Duman R.S. Voluntary exercise produces antidepressant and anxiolytic behavioral effects in mice. Brain Res. 2008, 1199:148-158.
48. Eisenberg M.E., Wall M., Neumark-Sztainer D. Muscle-enhancing behaviors among adolescent girls and boys. Pediatrics 2012, 130(6):1019-1026.
49. Engesser-Cesar C., Anderson A.J., Cotman C.W. Wheel running and fluoxetine antidepressant treatment have differential effects in the hippocampus and the spinal cord. Neuroscience 2007, 144(3):1033-1044.
50. Fitch K. Proscribed drugs at the Olympic Games: permitted use and misuse (doping) by athletes. Clin. Med. 2012, 2(3):257-260.
51. Forger N.G. The organizational hypothesis and final common pathways: sexual differentiation of the spinal cord and peripheral nervous system. Horm. Behav. 2009, 55(5):605-610.
52. Fox K. The influence of physical activity on mental well being. Public Health Nutr. 1999, 2(3A):411-418.
53. Fox J.H., Hammack S.E., Falls W.A. Exercise is associated with reduction in the anxiogenic effect of mCPP on acoustic startle. Behav. Neurosci. 2008, 122(4):943-948.
54. Frye C.A., Koonce C.J., Edinger K.L., Osborne D.M., Walf A.A. Androgens with activity at estrogen receptor beta have anxiolytic and cognitive-enhancing effects in male rats and mice. Horm. Behav. 2008, 54(5):726-734.
55. Fuss J., Ben Abdallah N.M., Vogt M.A., Touma C., Pacifici P.G., Palme R., Witzemann V., Hellweg R., Gass P. Voluntary exercise induces anxiety-like behavior in adult C57BL/6J mice correlating with hippocampal neurogenesis. Hippocampus 2010, 20(3):364-376.
56. Galligani N., Renck A., Hansen S. Personality profile of men using anabolic androgenic steroids. Horm. Behav. 1996, 30(2):170-175.
57. Geyer H., Parr M.K., Koehler K., Mareck U., Schänzer W. Nutritional supplements cross-contaminated and faked with doping substances. J. Mass Spectrom. 2008, 43:892-902.
58. Gilmore R.F., Varnum M.M., Forger N.G. Effects of blocking developmental cell death on sexually dimorphic calbindin cell groups in the preoptic area and bed nucleus of the stria terminalis. Biol. Sex Differ. 2012, 3:5.
59. Goldstein J.M., Seidman L.J., Horton N.J., Makris N., Kennedy D.N., Caviness V.S., Faraone S.V., Tsuang M.T. Normal sexual dimorphism of the adult human brain assessed by in vivo magnetic resonance imaging. Cereb. Cortex 2001, 11(6):490-497.
60. Goodfellow N.M., Benekareddy M., Vaidya V.A., Lambe E.K. Layer II/III of the prefrontal cortex: inhibition by the serotonin 5-HT1A receptor in development and stress. J. Neurosci. 2009, 29(32):10094-10103.
61. Grillon C. Models and mechanisms of anxiety: evidence from startle studies. Psychopharmacology 2008, 199:421-437.
62. Gustafsson S., Liang W., Hilke S. Effects of voluntary running in the female mice lateral septum on BDNF and corticotropin-releasing factor receptor 2. Int. J. Pept. 2011, 2011:932361. (doi: http://dx.doi.org/10.1155/2011/932361. Epub 2011 Sep 29).
63. Hall R.C., Hall R.C., Chapman M.J. Psychiatric complications of anabolic steroid abuse. Psychosomatics 2005, 46(4):285-290.
64. Hallberg M. Impact of anabolic androgenic steroids on neuropeptide systems. Mini-Rev. Med. Chem. 2011, 11(5):399-408.
65. Hamann S. Sex differences in the responses of the human amygdala. Neuroscientist 2005, 11(4):288-293.
66. Hammack S.E., Guo J.D., Hazra R., Dabrowska J., Myers K.M., Rainnie D.G. The response o neurons in the bed nucleus of the stria terminalis to serotonin: implications for anxiety. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33(8):1309-1320.
67. Harada N., Wakatsuki T., Aste N., Yoshimura N., Honda S.I. Functional analysis of neurosteroidal oestrogen using gene-disrupted and transgenic mice. J. Neuroendocrinol. 2009, 21(4):365-369.
68. Hauger R.L., Risbrough V., Brauns O., Dautzenberg F.M. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol Disord Drug Targets 2006, 5(4):453-479.
69. Hauger R.L., Risbrough V., Oakley R.H., Olivares-Reyes J.A., Dautzenberg F.M. Role of CRF receptor signaling in stress vulnerability, anxiety, and depression. Ann. N. Y. Acad. Sci. 2009, 1179:120-143.
70. Herring M.P., O'Connor P.J., Dishman R.K. The effect of exercise training on anxiety symptoms among patients: a systematic review. Arch. Intern. Med. 2010, 170(4):321-331.
71. Herring M.P., Jacob M.L., Suveg C., Dishman R.K., O'Connor P.J. Feasibility of exercise training for the short-term treatment of generalized anxiety disorder: a randomized controlled trial. Psychother. Psychosom. 2012, 81(1):21-28.
72. Hisasue S., Seney M.L., Immerman E., Forger N.G. Control of cell number in the bed nucleus of the stria terminalis of mice: role of testosterone metabolites and estrogen receptor subtypes. J. Sex. Med. 2010, 7(4 Pt 1):1401-1409.
73. Holsboer F., Ising M. Central CRH system in depression and anxiety-evidence from clinical studies with CRH1 receptor antagonists. Eur. J. Pharmacol. 2008, 583:350-357.
74. Hopkins M.E., Bucci D.J. BDNF expression in perirhinal cortex is associated with exercise-induced improvement in object recognition memory. Neurobiol. Learn. Mem. 2010, 94(2):278-284.
75. Hotta M., Shibasaki T., Masuda A., Imaki T., Demura H., Ling N., Shizume K. The responses of plasma adrenocorticotropin and cortisol to corticotropin-releasing hormone (CRH) and cerebrospinal fluid immunoreactive CRH in anorexia nervosa patients. J. Clin. Endocrinol. Metab. 1986, 62(2):319-324.
76. Ip E.J., Barnett M.J., Tenerowicz M.J., Perry P.J. The Anabolic 500 survey: characteristics of male users versus nonusers of anabolic-androgenic steroids for strength training. Pharmacotherapy 2011, 8:757-766.
77. Iwasaki-Sekino A., Mano-Otagiri A., Ohata H., Yamauchi N., Shibasaki T. Gender differences in corticotropin and corticosterone secretion and corticotropin-releasing factor mRNA expression in the paraventricular nucleus of the hypothalamus and the central nucleus of the amygdala in response to footshock stress or psychological stress in rats. Psychoneuroendocrinology 2009, 34(2):226-237.
78. Johnston L.D., O'Malley P.M., Bachman J.G., Schulenberg J.E. Monitoring the Future national survey results on drug use, 1975-2012. Secondary school students 2013, Volume I. Ann Arbor: Institute for Social Research, The University of Michigan, (604pp).
79. Kageyama K., Suda S. Transcriptional regulation of hypothalamic corticotropin-releasing fctor gene. Vitam. Horm. 2010, 82:301-317.
80. Kaye W.H., Gwirtsman H.E., George D.T., Ebert M.H., Jimerson D.C., Tomai T.P., Chrousos G.P., Gold P.W. Elevated cerebrospinal fluid levels of immunoreactive corticotropin-releasing hormone in anorexia nervosa: relation to state of nutrition, adrenal function, and intensity of depression. J. Clin. Endocrinol. Metab. 1987, 64(2):203-208.
81. Kaye W.H., Fudge J.L., Paulus M. New insights into symptoms and neurocircuit function of anorexia nervosa. Nat. Rev. Neurosci. 2009, 10(8):573-584.
82. Kim M.J., Gee D.G., Loucks R.A., Davis F.C., Whalen P.J. Anxiety dissociates dorsal and ventral medial prefrontal cortex functional connectivity with the amygdala at rest. Cereb. Cortex 2011, 21(7):1667-1673.
83. Koch M. The neurobiology of startle. Prog. Neurobiol. 1999, 59:107-128.
84. Kokkevi A., Fotiou A., Chileva A., Nociar A., Miller P. Daily exercise and anabolic steroids use in adolescents: a cross-national European study. Subst. Use Misuse 2008, 43(14):2053-2065.
85. Kouvelas D., Pourzitaki C., Papazisis G., Dagklis T., Dimou K., Kraus M.M. Nandrolone abuse decreases anxiety and impairs memory in rats via central androgenic receptors. Int. J. Neuropsychopharmacol. 2008, 11:925-934.
86. Laviola G., Macri S., Morley-Fletcher S., Adriani W. Risk-taking behavior in adolescent mice: psychobiological determinants and early epigenetic influence. Neurosci. Biobehav. Rev. 2003, 27:19-31.
87. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 1987, 92(2):180-185.
88. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2δδCT method. Methods 2001, 25:402-408.
89. Lund T.D., Munson D.J., Haldy M.E., Handa R.J. Androgen inhibits, while oestrogen enhances, restraint-induced activation of neuropeptide neurons in the paraventricular nucleus. J. Neuroendocrinol. 2004, 16:272-278.
90. Magalhaes A.C., Holmes K.D., Dale L.B., Comps-Agrar L., Lee D., Yadav P.N., Drysdale L., Poulter M.O., Roth B.L., Pin J.P., Anisman H., Ferguson S.S. CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nat. Neurosci. 2010, 13(5):622-629.
91. Manger T.A., Motta R.W. The impact of an exercise program on posttraumatic stress disorder, anxiety, and depression. Int. J. Emerg. Ment. Health 2005, 7(1):49-57.
92. Marlatt M.W., Potter M.C., Bayer T.A., van Praag H., Lucassen P.J. Prolonged running, not fluoxetine treatment, increases neurogenesis, but does not alter neuropathology, in the 3xTg mouse model of Alzheimer's Disease. Curr. Top. Behav. Neurosci. 2013, 15:313-340.
93. Martínez-Sanchis S., Salvador A., Moya-Albiol L., González-Bono E., Simón V.M. Effects of chronic treatment with testosterone propionate on aggression and hormonal levels in intact male mice. Psychoneuroendocrinology 1998, 23(3):275-293.
94. Matrisciano F., Modafferi A.M., Togna G.I., Barone Y., Pinna G., Nicoletti F., Scaccianoce S. Repeated anabolic androgenic steroid treatment causes antidepressant-reversible alterations of the hypothalamic-pituitary-adrenal axis, BDNF levels and behavior. Neuropharmacology 2010, 58(7):1078-1084.
95. Maue R.A., Burgess R.W., Wang B., Wooley C.M., Seburn K.L., Vanier M.T., Rogers M., Chang C.C., Chang T.-Y., Harris B.T., Graber D.J., Penatti C.A.A., Porter D.M., Szwergold B.S., Henderson L.P., Ohno-Iwashita Y., Totenhagen J., Trouard T., Borbon I., Erickson R.P. A novel mouse model of Niemann-Pick C disease carrying a A1005G-Npc1 mutation comparable to commonly observed human mutations. Hum. Mol. Genet. 2012, 21(4):730-750.
96. McDonald A.J., Shammah-lagnado S.J., Shi C., Davis M. Cortical afferents to the extended amygdala. Ann. N. Y. Acad. Sci. 1999, 877:309-338.
97. McGinnis M.Y. Anabolic androgenic steroids and aggression: studies using animal models. Ann. N. Y. Acad. Sci. 2004, 21036:399-415.
98. McGinnis M.Y., Lumia A.R., Tetel M.J., Molenda-Figueira H.A., Possidente B. Effects of anabolic androgenic steroids on the development and expression of running wheel activity and circadian rhythms in male rats. Physiol. Behav. 2007, 92(5):1010-1018.
99. Melloni R.H., Ricci L.A. Adolescent exposure to anabolic/androgenic steroids and the neurobiology of offensive aggression: a hypothalamic neural model based on findings in pubertal Syrian hamsters. Horm. Behav. 2010, 58(1):177-191.
100. Moy S.S., Nadler J.J., Perez A., Barbaro R.P., Johns J.M., Magnuson T.R., Piven J., Crawley J.N. Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Genes Brain Behav. 2004, 3:287-302.
101. Novak C.M., Burghardt P.R., Levine J.A. The use of a running wheel to measure activity in rodents: relationship to energy balance, general activity, and reward. Neurosci. Biobehav. Rev. 2012, 36:1001-1014.
102. Oberlander J.G., Henderson L.P. The Sturm und drang of anabolic steroid use: angst, anxiety, and aggression. Trends Neurosci. 2012, 35(6):382-392.
103. Oberlander J.G., Henderson L.P. Corticotropin releasing factor modulation of forebrain GABAergic transmission has a pivotal role in the expression of anabolic steroid-induced anxiety in the female mouse. Neuropsychopharmacology 2012, 37(6):1483-1499.
104. Oberlander J.G., Porter D.M., Onakomaiya M.M., Vithlani M., Moss S.J., Clark A.S., Henderson L.P. Estrous cycle variations in GABAA receptor phosphorylation enable rapid modulation by anabolic androgenic steroids in the medial preoptic area. Neuroscience 2012, 226:397-410.
105. Oberlander J.G., Porter D.M., Penatti C.A., Henderson L.P. Anabolic androgenic steroid abuse: multiple mechanisms of regulation of GABAergic synapses in neuroendocrine control regions of the rodent forebrain. J. Neuroendocrinol. 2012, 24(1):202-214.
106. Pagonis T.A., Angelopoulos N.V., Koukoulis G.N., Hadjichristodoulou C.S. Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlate to the severity of abuse. Eur. Psychiatry 2006, 21(8):551-562.
107. Palanza P. Animal models of anxiety and depression: how are females different?. Neurosci. Biobehav. Rev. 2001, 25(3):219-233.
108. Parkinson A.B., Evans N.A. Anabolic androgenic steroids: a survey of 500 users. Med. Sci. Sports Exerc. 2006, 38(4):644-651.
109. Pedersen B.K., Pedersen M., Krabbe K.S., Bruunsgaard H., Matthews V.B., Febbraio M.A. Role of exercise-induced brain-derived neurotrophic factor production in the regulation of energy homeostasis in mammals. Exp. Physiol. 2009, 94(12):1153-1160.
110. Peirson S.N., Butler J.N., Foster R.G. Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. Nucleic Acids Res. 2003, 31(14):e73.
111. Penatti C.A.A., Costine B.A., Porter D.M., Henderson L.P. Effects of chronic exposure to an anabolic androgenic steroid cocktail on α5-receptor mediated GABAergic transmission and neural signaling in the forebrain of female mice. Neuroscience 2009, 161:526-537.
112. Penatti C.A., Porter D.M., Henderson L.P. Chronic exposure to anabolic androgenic steroids alters neuronal function in the mammalian forebrain via androgen receptor- and estrogen receptor-mediated mechanisms. J. Neurosci. 2009, 29:12484-12496.
113. Penatti C.A.A., Oberlander J.G., Davis M.C., Porter D.M., Henderson L.P. Chronic exposure to anabolic androgenic steroids alters activity and synaptic function in neuroendocrine control regions of the female mouse. Neuropharmacology 2011, 61(4):653-664.
114. Pigott T.A. Gender differences in the epidemiology and treatment of anxiety disorders. J. Clin. Psychiatry 1999, 60(18):4-15.
115. Pope H.G., Katz D.L. Affective and psychotic symptoms associated with anabolic steroid use. Am. J. Psychiatry 1988, 145(4):487-490.
116. Pope H.G., Kanayama G., Athey A., Ryan E., Hudson J.I., Baggish A. Lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: current best estimates. Am. J. Addict. 2013, (2013 Sep 20. doi: http://dx.doi.org/10.1111/j.1521-0391.2013.12118.x. [Epub ahead of print]).
117. Reul J.M.H.M., Holsboer F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr. Opin. Pharmacol. 2002, 2:23-33.
118. Robinson S., Penatti C.A., Clark A.S. The role of the androgen receptor in anabolic androgenic steroid-induced aggressive behavior in C57BL/6J and Tfm mice. Horm. Behav. 2012, 61(1):67-75.
119. Rocha V.M., Calil C.M., Ferreira R., Moura M.J.C.S., Marcondes F.K. Influence of anabolic steroid on anxiety levels in sedentary male rats. Stress 2007, 10:326-331.
120. Rojas-Ortiz Y.A., Rundle-Gonzalez V., Rivera-Ramos I., Jorge J.C. Modulation of elevated plus maze behavior after chronic exposure to the anabolic steroid 17α-methyltestosterone in adult mice. Horm. Behav. 2006, 49:123-128.
121. Rossbach U.L., Steensland P., Nyberg F., Le Grevès P. Nandrolone-induced hippocampal phosphorylation of NMDA receptor subunits and ERKs. Biochem. Biophys. Res. Commun. 2007, 357(4):1028-1033.
122. Salam J.N., Fox J.H., Detroy E.M., Guignon M.H., Wohl D.F., Falls W.A. Voluntary exercise in C57 mice is anxiolytic across several measures of anxiety. Behav. Brain Res. 2009, 197(1):31-40.
123. Sartori C.R., Vieira A.S., Ferrari E.M., Langone F., Tongiorgi E., Parada C.A. The antidepressive effect of the physical exercise correlates with increased levels of mature BDNF, and proBDNF proteolytic cleavage-related genes, p11 and tPA. Neuroscience 2011, 180:9-118.
124. Sato S.M., Schulz K.M., Sisk C.L., Wood R.I. Adolescents and androgens, receptors and rewards. Horm. Behav. 2008, 53(5):647-658.
125. Shekhar A., Truitt W., Rainnie D., Sajdyk T. Role of stress, corticotrophin releasing factor (CRF) and amygdala plasticity in chronic anxiety. Stress 2005, 8(4):209-219.
126. Simonds V.M., Whiffen V.E. Are gender differences in depression explained by gender differences in co-morbid anxiety?. J. Affect. Disord. 2003, 77(3):197-202.
127. Steensland P., Blakely G., Nyberg F., Fahlke C., Pohorecky L.A. Anabolic androgenic steroid affects social aggression and fear-related behaviors in male pair-housed rats. Horm. Behav. 2005, 48:216-224.
128. Sterrenburg L., Gaszner B., Boerrigter J., Santbergen L., Bramini M., Elliott E., Chen A., Peeters B.W., Roubos E.W., Kozicz T. Chronic stress induces sex-specific alterations in methylation and expression of corticotropin-releasing factor gene in the rat. PLoS One 2011, 6(11):e28128.
129. Su T.P., Pagliaro M., Schmidt P.J., Pickar D., Wolkowitz O., Rubinow D.R. Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA 1993, 269(21):2760-2764.
130. Tan H., Zhong P., Yan Z. Corticotropin-releasing factor and acute stress prolongs serotonergic regulation of GABA transmission in prefrontal cortical pyramidal neurons. J. Neurosci. 2004, 24(21):5000-5008.
131. Tanehkar F., Rashidy-Pour A., Vafaei A.A., Sameni H.R., Haghighi S., Miladi-Gorji H., Motamedi F., Akhavan M.M., Bavarsad K. Voluntary exercise does not ameliorate spatial learning and memory deficits induced by chronic administration of nandrolone decanoate in rats. Horm. Behav. 2013, 63(1):158-165.
132. Tanner S.M., Miller D.W., Alongi C. Anabolic steroid use by adolescents: prevalence, motives, and knowledge of risks. Clin. J. Sport Med. 1995, 5(2):108-115.
133. ter Horst J.P., Carobrez A.P., van der Mark M.H., de Kloet E.R., Oitzl M.S. Sex differences in fear memory and extinction of mice with forebrain-specific disruption of the mineralocorticoid receptor. Eur. J. Neurosci. 2012, 36(8):3096-3102.
134. Toufexis D. Region- and sex-specific modulation of anxiety behaviors in the rat. J. Neuroendocrinol. 2007, 19(6):461-473.
135. Valentino R.J., Reyes B., Van Bockstaele E., Bangasser D. Molecular and cellular sex differences at the intersection of stress and arousal. Neuropharmacology 2012, 62(1):13-20.
136. Valentino R.J., Bangasser D., Van Bockstaele E.J. Sex-biased stress signaling: the corticotropin-releasing factor receptor as a model. Mol. Pharmacol. 2013, 83(4):737-745.
137. vandenBerg P., Neumark-Sztainer D., Cafri G., Wall M. Steroid use among adolescents: longitudinal findings from Project EAT. Pediatrics 2007, 119(3):476-486.
138. Vertes R.P. Differential projections of the infralimbic and prelimbic cortex in the rat. Synapse 2004, 51(1):32-58.
139. Viau V., Bingham B., Davis J., Lee P., Wong M. Gender and puberty interact on the stress-induced activation of parvocellular neurosecretory neurons and corticotropin-releasing hormone messenger ribonucleic acid expression in the rat. Endocrinology 2005, 146(1):137-146.
140. Walf A.A., Frye C.A. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat. Protoc. 2007, 2(2):322-328.
141. Walker D.L., Miles L.A., Davis M. Selective participation of the bed nucleus of the stria terminalis in anxiety-like versus phasic fear-like responses. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2009, 33:1291-1308.
142. Wood R.I. Anabolic-androgenic steroid dependence? Insights from animals and humans. Front. Neuroendocrinol. 2008, 29(4):490-506.
143. Wood R.I., Stanton S.J. Testosterone and sport: current perspectives. Horm. Behav. 2012, 61:147-155.
144. Zajac M.S., Pang T.Y., Wong N., Weinrich B., Leang L.S., Craig J.M., Saffery R., Hannan A.J. Wheel running and environmental enrichment differentially modify exon-specific BDNF expression in the hippocampus of wild-type and pre-motor symptomatic male and female Huntington's disease mice. Hippocampus 2010, 20(5):621-636.
145. Zoladz J.A., Pilc A. The effect of physical activity on the brain derived neurotrophic factor: from animal to human studies. J. Physiol. Pharmacol. 2010, 61(5):533-541.